Workflow
虚拟医疗
icon
Search documents
LifeMD Inc (NASDAQ:LFMD) Targets Substantial Growth in the Virtual Healthcare Sector
Financial Modeling Prep· 2025-11-25 03:06
Core Insights - LifeMD Inc is a significant player in the virtual healthcare industry, recognized for its innovative telehealth platform and strong revenue growth, earning spots on the 2025 Deloitte Technology Fast 500 and TIME's America's Growth Leaders of 2026 lists [1][5] Financial Performance - On November 24, 2025, Loop Capital Markets set a price target of $8 for LFMD, indicating a potential price increase of about 98.49% from its trading price of $3.97, reflecting the company's robust market position [2][5] - LifeMD's stock has shown volatility, with a recent price range between $3.91 and $4.06, and a 3.12% increase over a recent period, with a change of $0.12 [3] - Over the past year, LFMD's stock has fluctuated significantly, reaching a high of $15.84 and a low of $3.43, indicating substantial growth potential [3][5] Market Position and Strategy - The company's market capitalization is approximately $191.1 million, with a trading volume of 1,106,676 shares, positioning it well for future success [4] - LifeMD is focusing on expanding its offerings in high-growth markets such as weight management and mental health, which supports the positive price target set by Loop Capital Markets [4]
股价盘前劲涨 DocGo(DCGO.US)收购虚拟医疗平台SteadyMD
智通财经网· 2025-10-21 11:16
Core Viewpoint - DocGo has announced the acquisition of virtual healthcare platform SteadyMD, leading to a significant increase in its stock price, which rose by 48% at one point during pre-market trading [1] Group 1: Acquisition Details - The acquisition will be funded through existing cash on DocGo's balance sheet [1] - SteadyMD is projected to generate approximately $25 million in revenue by 2025, with a positive EBITDA expected in 2026 [1] - Following the acquisition, key executives from SteadyMD, including CEO Guy Friedman and COO Yarone Goren, will join DocGo's leadership team [1] Group 2: Financial Guidance - DocGo plans to update its revenue and adjusted EBITDA guidance for 2025 to reflect the impact of the acquisition during its upcoming earnings report and conference call, scheduled for early November [1]